Cell. 2009 May 29;137(5):796-8.

Finding and drugging the vulnerabilities of RAS-dependent cancers.

Source

Howard Hughes Medical Institute, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. sawyersc@mskcc.org

Abstract

Kinase inhibitors have ushered in the era of targeted therapy, but their utility to date is primarily limited to cancers bearing oncogenic kinase mutations. Two papers in this issue (Luo et al., 2009; Scholl et al., 2009) could change this landscape by uncovering kinase-specific vulnerabilities in tumors with RAS mutations.

Comment on

PMID:: 19490885; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. [Cell. 2009]
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C, Fröhling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, et al. Cell. 2009 May 29; 137(5):821-34.
Using cells devoid of RAS proteins as tools for drug discovery. [Mol Carcinog. 2009]
Using cells devoid of RAS proteins as tools for drug discovery.
Urosevic J, Sum EY, Moneo V, Drosten M, Dhawahir A, Becerra M, Carnero A, Barbacid M. Mol Carcinog. 2009 Nov; 48(11):1038-47.
K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. [Mol Cancer Res. 2009]
K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways.
Matsuo Y, Campbell PM, Brekken RA, Sung B, Ouellette MM, Fleming JB, Aggarwal BB, Der CJ, Guha S. Mol Cancer Res. 2009 Jun; 7(6):799-808. Epub 2009 Jun 9.
Review Interfering with protein-protein interactions: potential for cancer therapy. [Cell Cycle. 2008]
Review Interfering with protein-protein interactions: potential for cancer therapy.
Tanaka T, Rabbitts TH. Cell Cycle. 2008 Jun 1; 7(11):1569-74. Epub 2008 Apr 2.
Review Ras signaling and therapies. [Adv Cancer Res. 2009]
Review Ras signaling and therapies.
Young A, Lyons J, Miller AL, Phan VT, Alarcón IR, McCormick F. Adv Cancer Res. 2009; 102:1-17.

See reviews... See all...

Cited by 2 PubMed Central articles

KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations. [Genes Cancer. 2011]
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations.
O'Hagan RC, Heyer J. Genes Cancer. 2011 Mar; 2(3):335-43.
Synthetic Lethality Induced by Loss of PKC δ and Mutated Ras. [Genes Cancer. 2010]
Synthetic Lethality Induced by Loss of PKC δ and Mutated Ras.
Zhu T, Chen L, Du W, Tsuji T, Chen C. Genes Cancer. 2010 Feb; 1(2):142-51.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Finding and drugging the vulnerabilities of RAS-dependent cancers.
Finding and drugging the vulnerabilities of RAS-dependent cancers.
Cell. 2009 May 29 ;137(5):796-8.

PubMed
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with...
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Cell. 2009 May 29 ;137(5):835-48.

PubMed
Integrating genetic approaches into the discovery of anticancer drugs.
Integrating genetic approaches into the discovery of anticancer drugs.
Science. 1997 Nov 7 ;278(5340):1064-8.

PubMed
The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco...
The limited relevance of drug policy: cannabis in Amsterdam and in San Francisco.
Am J Public Health. 2004 May ;94(5):836-42.

PubMed
Do medical cannabis laws encourage cannabis use?
Do medical cannabis laws encourage cannabis use?
Int J Drug Policy. 2007 May ;18(3):160-7. Epub 2006 Nov 15 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: